Loading stock data…
CGON
$66.27-0.47 (-0.70%)
Market ClosedLast close May 1
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CG Oncology, Inc. in the Healthcare sector is trading at $66.27. The stock is currently near its 52-week high of $73.56, remaining 44.4% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why CGON maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$66.27
Potential Upside
5%
Whystock Fair Value$69.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$87.86+32.6%
Range$70.00 – $108.00
Fundamentals
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigationa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.90B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.39%
Volume
Today's trading volume
780,962
Recent News
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know
CG Oncology, Inc. (CGON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is CG Oncology’s New CFO Hire (CGON) Reframing Its Oncolytic Immunotherapy Investment Story?
On April 13, 2026, CG Oncology, Inc. appointed experienced biotechnology finance executive Jim DeTore as its Chief Financial Officer, formalizing a role he had held on an interim basis since November 2025. His background leading finance functions at multiple early and mid-stage biotech companies adds seasoned capital allocation and reporting expertise as CG Oncology advances its oncolytic immunotherapy programs. With this leadership change and recent pivotal clinical data exceeding...
CG Oncology (CGON) Rallied on Pivotal Clinical Results
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter is available to download here. The US equities market started 2026 with volatility driven by trade policy uncertainty and heightened geopolitical risks. Initial gains were attributed to confidence in domestic companies and the […]
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.